Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Laxido Orange is an osmotic laxative developed and marketed by Galen Limited. It is a branded generic formulation of the macrogol 3350 plus electrolytes combination, similar to the original brand Movicol. The product contains macrogol 3350 (polyethylene glycol 3350) along with sodium chloride, sodium hydrogen carbonate, and potassium chloride. It is indicated for the treatment of chronic constipation and faecal impaction in adults, adolescents (12 years and older), and the elderly. The mechanism of action involves macrogol 3350 acting as an osmotic agent that draws water into the bowel, thereby increasing stool volume and softening it to facilitate evacuation. The inclusion of electrolytes helps to maintain the body's normal levels of sodium, potassium, and water during treatment, minimizing the risk of electrolyte imbalance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Laxido Orange.